Clinical Cancer Research

Table of Contents

American Association for Cancer Research

April 1, 2014 • Volume 20 • Number 7

Highlights of This Issue 1707

SPECIAL FEATURES

Special Report

1709 AACR Celebrates 50 Years of Tobacco Research and Policy
Roy S. Herbst, Jennifer A. Hobin, and Ellen R. Gritz; Writing Committee for the AACR Subcommittee on Tobacco and Cancer

Special Commentary

1719 It Shouldn't Take Another 50 Years: Accelerating Momentum to End the Tobacco Epidemic
Howard K. Koh

CCR Translations

1721 Seeing the Forest for the Trees: Kidney Oncogenomes in Relation to Therapeutic Outcomes
David D. Chism and W. Kimryn Rathmell
See related article, p. 1955

1724 Estrogen Receptor Mutations in Breast Cancer—New Focus on an Old Target
Corrinne V. Segal and Mitch Dowsett
See related article, p. 1757

1727 Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?
Paul A. Bunn Jr, Fred R. Hirsch, and Dara L. Aisner
See related article, p. 1946

Statistics in Clinical Cancer Research

1730 Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials
Cong Chen and Robert A. Beckman

CCR Drug Updates

1735 Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
Varsha Gandhi, William Plunkett, and Jorge E. Cortes

Molecular Pathways

1741 Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer
Silvana Paredes, Lidia Villanova, and Katrin F. Chua

Review

1747 CME Intratumoral Immunization: A New Paradigm for Cancer Therapy
Aurélien Marabelle, Holbrook Kohrt, Christophe Caux, and Ronald Levy

HUMAN CANCER BIOLOGY

1757 Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett Frampton, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A. Perez-Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer Giltnane, Justin M. Balko, Maureen T. Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan-Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, and Vincent A. Miller
See related article, p. 1724

1768 T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Rikke Lyngaa, Natasja Wulff Pedersen, David Schrama, Charlotte Albæk Thrue, Dafina Ibrani, Özcan Met, Per thor Straten, Paul Nghiem, Jürgen C. Becker, and Sine Reker Hadrup

1779 Downregulation of FOXO3a Promotes Tumor Metastasis and Is Associated with Metastasis-Free Survival of Patients with Clear Cell Renal Cell Carcinoma
Dong Ni, Xin Ma, Hong-Zhao Li, Yu Gao, Xin-Tao Li, Yu Zhang, Qing Ai, Peng Zhang, Er-Lin Song, Qing-Bo Huang, Yang Fan, and Xu Zhang

Table of Contents

1791 **Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer**
Tobias Lange, Mareike Kupfernagel, Daniel Wicklein, Florian Gebauer, Hanna Maar, Kathrin Brügge, Imke Müller, Ronald Simon, Thorsten Schlomm, Guido Sauter, and Udo Schumacher

1803 **Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting *PIK3CD* and Predicts the Prognosis of Human Glioblastoma**
Yu Shi, Cong Chen, Xia Zhang, Qing Liu, Jin-Ling Xu, Hua-Rong Zhang, Xiao-Hong Yao, Tao Jiang, Zhi-Cheng He, Yong Ren, Wei Cui, Chuan Xu, Ling Liu, You-Hong Cui, Shi-Zhu Yu, Yi-Fang Ping, and Xiu-Wu Bian

CANCER THERAPY: PRECLINICAL

1814 **Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma**
Naoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino, Kentaro Yamanaka, Aya Kita, Masamichi Mori, Sosuke Miyoshi, and Sadao Kuromitsu

1823 **A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor–Infiltrating Lymphocytes**
Nathalie Demotte, René Bigirimana, Grégoire Wieërs, Vincent Stroobant, Jean-Luc Squifflet, Javier Carrasco, Kris Thielemans, Jean-François Baurain, Patrick Van Der Smissen, Pierre J. Courtoy, and Pierre van der Bruggen

1834 **Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers**
Pablo D. Garcia, John L. Langowski, Yingyun Wang, Min Chen, Joseph Castillo, Christie Fanton, Marjorie Ison, Tatiana Zavorotinskaya, Yumin Dai, Jing Lu, Xiao-Hong Niu, Stephen Basham, Julie Chan, Jianjun Yu, Michael Doyle, Paul Feucht, Robert Warne, Jamie Narberes, Tiffany Tsang, Christine Fritsch, Audrey Kauffmann, Estelle Pfister, Peter Drueckes, Joerg Trappe, Christopher Wilson, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Mika Lindvall, Cornelia Bellamacina, J. Alex Aycinena, Richard Zang, Jocelyn Holash, and Matthew T. Burger

1846 **Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib**
Jie Huang, Wei Hu, Justin Bottsford-Miller, Tao Liu, Hee Dong Han, Behrouz Zand, Sunila Pradeep, Ju-Won Roh, Duangmani Thanapprapasr, Heather J. Dalton, Chad V. Pecot, Rajesh Rupaimoole, Chunhua Lu, Bryan Fellman, Diana Urbauer, Yu Kang, Nicholas B. Jennings, Li Huang, Michael T. Deavers, Russell Broaddus, Robert L. Coleman, and Anil K. Sood

IMAGING, DIAGNOSIS, PROGNOSIS

1856 **Functional Identification of Cancer-Specific Methylation of *CDO1*, *HOXA9*, and *TAC1* for the Diagnosis of Lung Cancer**
John Wrangle, Emi Ota Machida, Ludmila Danilova, Alicia Hulbert, Noreli Franco, Wei Zhang, Sabine C. Glöckner, Mathewos Tessema, Leander Van Neste, Hariharan Easwaran, Kornel E. Schuebel, Julien Licchesi, Craig M. Hooker, Nita Ahuja, Jun Amano, Steven A. Belinsky, Stephen B. Baylin, James G. Herman, and Malcolm V. Brock

1865 **Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis**
Haeryoung Kim, Burcu Saka, Spencer Knight, Michael Borges, Erica Childs, Alison Klein, Christopher Wolfgang, Joseph Herman, Volkan N. Adsay, Ralph H. Hruban, and Michael Goggins

1873 **Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma**
Markus Riester, Lillian Werner, Joaquim Bellmunt, Shamini Selvarajah, Elizabeth A. Guancial, Barbara A. Weir, Edward C. Stack, Rachel S. Park, Robert O'Brien, Fabio A.B. Schutz, Toni K. Choueiri, Sabina Signoretti, Josep Lloreta, Luigi Marchionni, Enrique Gallardo, Federico Rojo, Denise I. Garcia, Yvonne Chekaluk, David J. Kwiatkowski, Bernard H. Bochner, William C. Hahn, Azra H. Ligon, Justine A. Barletta, Massimo Loda, David M. Berman, Philip W. Kantoff, Franziska Michor, and Jonathan E. Rosenberg

Table of Contents

1884 **Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma**
Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, and Andrew X. Zhu

1891 **Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer**
Maria-Gabriela Anitei, Guy Zeitoun, Bernhard Mlecnik, Florence Marliot, Nacilla Haicheur, Ana-Maria Todosi, Amos Kirilovsky, Christine Lagorce, Gabriela Bindea, Dan Ferariu, Mihai Danciu, Patrick Bruneval, Viorel Scripcariu, Jean-Marc Chevallier, Franck Zinzindohoué, Anne Berger, Jérôme Galon, and Franck Pagès

CANCER THERAPY: CLINICAL

1900 **A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors**
Jordi Rodon, Hussein A. Tawbi, Anne L. Thomas, Ronald G. Stoller, Christian P. Turtschi, Jose Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine L. Rose, Dereck D. Amakye, Reinhard Dummer, and Alain C. Mita

1910 **Topical Application of a Mucoadhesive Freeze-Dried Black Raspberry Gel Induces Clinical and Histologic Regression and Reduces Loss of Heterozygosity Events in Premalignant Oral Intraepithelial Lesions: Results from a Multicentered, Placebo-Controlled Clinical Trial**
Susan R. Mallery, Meng Tong, Brian S. Shumway, Alice E. Curran, Peter E. Larsen, Gregory M. Ness, Kelly S. Kennedy, George H. Blakey, George M. Kushner, Aaron M. Vickers, Brian Han, Ping Pei, and Gary D. Stoner

1925 **Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer**
Johann S. de Bono, Josep M. Piulats, Hardev S. Pandha, Daniel P. Petrylak, Fred Saad, Luis Miguel A. Aparicio, Shahneen K. Sandhu, Peter Fong, Silke Gillessen, Gary R. Hudes, Tao Wang, Judith Scranton, and Michael N. Pollak

1935 **Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy**
Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhua Ru, Stefan De Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea, Joseph T. Beck, Emmanuelle Di Tomaso, David W. Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, and Jose Baselga

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

1946 **Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy**
Kathryn A. Gold, Edward S. Kim, Diane D. Liu, Ping Yuan, Carmen Behrens, Luisa M. Solis, Humam Kadara, David C. Rice, Ignacio I. Wistuba, Stephen G. Swisher, Wayne L. Hofstetter, J. Jack Lee, and Waun K. Hong
See related article, p. 1727

1955 **Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy**
Martin H. Voss, A. Ari Hakimi, Can G. Pham, A. Rose Brannon, Ying-Bei Chen, Luis F. Cunha, Oguz Akin, Han Liu, Shugaku Takeda, Sasinya N. Scott, Nicholas D. Socci, Agnes Viale, Nikolaus Schultz, Chris Sander, Victor E. Reuter, Paul Russo, Emily H. Cheng, Robert J. Motzer, Michael F. Berger, and James J. Hsieh
See related article, p. 1721

1965 **BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact**
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie Howle, Robyn Saw, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, and Georgina V. Long

Table of Contents

1978 **A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence**
Sheng-Fang Su, André Luís de Castro Abreu, Yoshitomo Chihara, Yvonne Tsai, Claudia Andreu-Vieyra, Siamak Daneshmand, Eila C. Skinner, Peter A. Jones, Kimberly D. Siegmund, and Gangning Liang

1990 **Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11**
Ross M. Drayton, Ewa Dudziec, Stefan Peter, Simone Bertz, Arndt Hartmann, Helen E. Bryant, and James WF. Catto

2001 **The Impact of *EGFR* T790M Mutations and *BIM* mRNA Expression on Outcome in Patients with *EGFR*-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial**
Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez-Capitán, Jordi Bertran-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massuti, Jia Wei, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario Garcia-Campelo, Santiago Viteri, Miquel Taron, Mayumi Ono, Petros Giannikopoulos, Trever Bivona, and Rafael Rosell

LETTERS TO THE EDITOR

2011 **Definition of Primary and Secondary Glioblastoma—Letter**
Peter Werner, Dominik Fritzsch, Heidrun Holland, Manfred Bauer, Wolfgang Krupp, Karl-Titus Hoffmann, Dorothee Saur, Florian Then Bergh, Osama Sabri, and Henryk Barthel

2013 **Definition of Primary and Secondary Glioblastoma—Response**
Hiroko Ohgaki, Peter Burger, and Paul Kleihues

2014 **Novel Clinically Relevant Genes in GIST—Letter**
M.A. Pantaleo, M. Nannini, A. Astolfi, and G. Biasco

2015 **Novel Clinically Relevant Genes in GIST—Response**
Peter Birner and Berthold Streubel

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a lymph node metastasis from a patient with prostate cancer. Lectin histochemistry with *Helix pomatia* agglutinin shows a decreasing surface presentation of terminal GalNAc- and GlcNAc-residues in lymph node metastasis. In conjunction with this finding, the authors demonstrate that metastatic prostate cancer cells can extravasate in the absence of selectins. For details, see the article by Lange and colleagues on page 1791 of this issue.